G89.4 Insurance Policy Changes

ICD-10 G89.4 is officially defined as "Chronic pain syndrome." code G89.4 is referenced in 22 tracked payer policy changes from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G89.4 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Oct 22, 2026Medium impact
Urine Drug Testing 2.02.50
Excellus BlueCross BlueShield policy 2.02.50 for urine drug testing considers in-office or point-of-care presumptive immunoassay urine drug testing medically appropriate for outpatient pain management and for outpatient substance use treatment, both for baseline screening and for ongoing monitoring at a frequency matched to the patient's risk. Definitive urine drug testing is considered medically appropriate when presumptive testing cannot identify a specific substance or drug, when a definitive drug concentration is needed to guide management, to rule out an error as the cause of a qualitative result, or as part of a differential assessment of medication efficacy, side effects, or drug-drug interactions. The October 22, 2026 version is recorded as an annual review with the policy intent unchanged.
Blue Cross & Blue Shield of Mississippi · Effective Jan 1, 2026Medium impact
Urine Drug Testing
Blue Cross Blue Shield Association policy 2.04.98 added CPT 0603U, a presumptive drug assay of 77 drugs or metabolites in urine by LC-MS/MS reported as positive or negative, which the code table lists as new as of 01/01/2026 and as investigational. The policy considers routine presumptive urine drug testing not medically necessary in chronic non-cancer pain management and substance use disorder treatment, and considers hair drug testing and oral fluid drug testing investigational in both settings. Presumptive urine drug testing is medically necessary only for the baseline screening and monitoring frequencies the policy lists for each setting.
Independence Blue Cross · Effective Dec 29, 2025Medium impact
MA05.006l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
Independence Blue Cross reissued MA05.006l on 10/28/2026 to communicate its continuing position on TENS coverage; the policy itself became effective 12/29/2025 with clarified medically necessary criteria for chronic pain (other than low back pain) and revised experimental/investigational criteria. A specific criterion requiring ≥50% pain reduction has been deleted from the medically necessary section, streamlining approval requirements for TENS trial periods.
Independence Blue Cross · Effective Dec 29, 2025Medium impact
05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
Independence Blue Cross revised policy 05.00.74l for TENS devices effective 12/29/2025, clarifying medically necessary criteria for chronic pain (other than lower back pain) and experimental/investigational criteria. The policy REMOVED the requirement for demonstrating at least 50% pain reduction with objective evidence (e.g., decreased opioid usage, improved range of motion, VAS scores) as a continuation criterion after the initial trial period. Billing teams must update their prior authorization and claims review processes to align with the relaxed documentation requirements for continued TENS coverage.
Independence Blue Cross · Effective Oct 1, 2025Medium impact
MA05.006k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
Independence Blue Cross updated MA05.006k to MA05.006l, effective 10/01/2025, replacing the broad ICD-10 code R10.2 (pelvic and perineal pain) with four more specific codes (R10.21, R10.22, R10.23, R10.24) for TENS device coverage criteria. This is an ICD-10 code maintenance update that requires billing teams to use laterality-specific and anatomically precise codes when documenting TENS eligibility for pelvic/perineal pain conditions.
Aetna · Identified Oct 28, 2026Medium impact
Motor Cortex Stimulation (CPB 0755, reviewed 2026-10-21)
Aetna's Clinical Policy Bulletin 0755 says Aetna considers motor cortex stimulation experimental, investigational, or unproven for the listed indications because its effectiveness has not been established. The listed indications include amyotrophic lateral sclerosis, autism spectrum disorder, cerebral palsy, chronic refractory pain, depression, dysphagia, Parkinson's disease, post-stroke aphasia, post-stroke hemiparesis, seizures, traumatic brain injury and obsessive compulsive disorder, and the bulletin says that list is not all-inclusive. The bulletin also lists CPT, HCPCS and ICD-10 codes that are not covered for the indications listed in the policy.
Aetna · Identified Oct 22, 2026Medium impact
Ziconotide (Prialt) (CPB 0712, reviewed 2026-10-14)
Aetna considers intrathecal ziconotide (Prialt) medically necessary for members with severe chronic pain that is intolerant of or refractory to other treatments, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Aetna considers it not medically necessary for members with a pre-existing history of psychosis, an infection at the micro-infusion injection site, uncontrolled bleeding diathesis, or spinal canal obstruction. Aetna considers intrathecal ziconotide experimental, investigational, or unproven for autism, epilepsy, Irukandji syndrome, migraines, primary lateral sclerosis, stroke and other indications, and considers the intrathecal combination of ziconotide, morphine and levobupivacaine experimental for cancer-related refractory pain.
Aetna · Identified Oct 16, 2026Medium impact
Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-10-14)
Aetna considers TENS units medically necessary durable medical equipment when used as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic, intractable pain not adequately responsive to other methods. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when all listed criteria are met. Percutaneous electrical nerve stimulation is considered medically necessary for chronic low back pain secondary to degenerative disc disease for up to a 30-day period within a multi-modality rehabilitation program, and for diabetic neuropathy or neuropathic pain that has not responded to listed medications. Many other electrical stimulation devices and indications are listed as experimental, investigational, or unproven.
Aetna · Identified Oct 1, 2026Medium impact
Drug Testing in Pain Management and Substance Use Disorder Treatment (CPB 0965, reviewed 2026-09-01)
Aetna considers presumptive urine drug testing medically necessary for people in a chronic pain or substance use disorder program when an indication applies, such as starting treatment in the program, suspected illegal or non-prescribed substance use, suspected overdose, monitoring of chronic opioid therapy, or testing documented as part of an active treatment plan. Definitive or confirmatory urine testing is medically necessary only for people who meet the presumptive testing criteria and also have a listed indication, such as no commercially available presumptive test, an inconclusive or inconsistent presumptive result, or a disputed presumptive result. Testing ordered by courts, schools, employers or other third parties is considered not medically necessary.
Aetna · Identified Aug 18, 2026Medium impact
Thalamotomy (CPB 0153, reviewed 2026-03-30)
Aetna considers unilateral thalamotomy medically necessary for abolishing tremor and rigidity in members with dystonia, Parkinson's disease, spasmodic torticollis, or tremor who meet all listed selection criteria, including a positive initial response to medication that later became refractory, screening by a neurologist with movement disorders expertise, and severe, incapacitating tremor where medical therapy has failed. Focused ultrasound thalamotomy is covered for severe essential tremor inadequately responsive to medical therapy, gamma knife thalamotomy is covered for severe essential tremor or for refractory disabling tremor and rigidity from Parkinson's disease, and thalamotomy is covered as a last resort for malignant pain when all listed criteria are met. Bilateral thalamotomy, focused ultrasound thalamotomy for tremor syndromes other than essential tremor, and thalamotomy for non-malignant pain are considered experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Nerve Blocks (CPB 0863, reviewed 2026-07-23)
Aetna Clinical Policy Bulletin 0863 covers nerve blocks and lists which ones it considers medically necessary. Covered uses include adductor canal, femoral, fascia iliaca, erector spinae plane and transversus abdominis plane blocks for post-operative pain after specific surgeries, and celiac plexus block for cancer pain, while peripheral nerve blocks for chronic pain are covered only as an active component of a comprehensive pain management program. Blocks listed as experimental and investigational include genicular nerve blocks and peripheral nerve blocks used as the sole treatment for chronic non-malignant pain, because the effectiveness of these approaches has not been established.
Aetna · Identified Aug 17, 2026Medium impact
Motor Cortex Stimulation (CPB 0755, reviewed 2026-02-24)
Aetna's Clinical Policy Bulletin 0755 on motor cortex stimulation, with a policy history last review of 10/21/2026, considers motor cortex stimulation experimental, investigational or unproven for many indications because its effectiveness has not been established. The list includes amyotrophic lateral sclerosis, autism spectrum disorder, cerebral palsy, chronic refractory pain (such as central pain syndromes, complex regional pain syndrome, phantom limb pain, thalamic pain and trigeminal neuropathic pain), depression, dysphagia, dystonia secondary to a focal basal ganglia lesion, movement disorders, obsessive compulsive disorder, Parkinson's disease, post-stroke aphasia, post-stroke hemiparesis, seizures, traumatic brain injury, and use of motor cortex stimulation during deep brain stimulator implantation. The policy lists CPT codes 61850, 61860, 61885, 61886, 64568, 95961, 95962 and 95970 as not covered for the indications it lists.
Aetna · Identified Aug 16, 2026Medium impact
Seat Lifts and Patient Lifts (CPB 0459, reviewed 2026-07-16)
Aetna covers seat lift mechanisms as durable medical equipment only when the member cannot stand up from a regular armchair at home, has severe arthritis of the hip or knee or severe neuromuscular disease, the device is prescribed to effect improvement or arrest or slow deterioration, and the member can ambulate once standing. Stand-assist lifts, patient lifts, bariatric lifts, and multi-positional transfer systems are covered only when their own separate criteria are met, and spring-release seat lifts with a catapult-type motion are considered experimental, investigational, or unproven. the policy was last reviewed 07/16/2026.
Aetna · Identified Aug 16, 2026Medium impact
Laboratory Tests for Depression and Other Psychiatric Disorders (CPB 0306, reviewed 2026-06-08)
Aetna considers the dexamethasone suppression test medically necessary only when a psychiatrist requests it to differentiate psychotic depression from schizophrenia. The policy considers the test experimental, investigational, or unproven for diagnosing major depressive disorder, selecting medications for major depressive illness, and diagnosing or managing borderline personality disorder or post-traumatic stress syndrome. It also considers MindX blood tests, microRNA measurement, neutrophil-to-lymphocyte, monocyte-to-lymphocyte and platelet-to-lymphocyte ratios for diagnosing depression, and the TruD MDS bipolar, major depressive disorder and schizophrenia tests experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)
Aetna's commercial clinical policy bulletin 0844 covers fecal bacteriotherapy. It considers fecal microbiota transplant medically necessary for Clostridium difficile infection (CDI) confirmed by a positive C. difficile toxin stool test that has recurred after at least one course of adequate antibiotic therapy. It considers a single rectal dose of Rebyota (fecal microbiota, live-jslm) medically necessary for preventing CDI when the policy's criteria are met, and it considers other listed indications, including alcoholic hepatitis, Crohn's disease, ulcerative colitis and irritable bowel syndrome, experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)
Aetna covers alternative medicine interventions when they are supported by adequate evidence of safety and effectiveness in the peer-reviewed published medical literature, subject to benefit plan limitations and exclusions. Acupuncture, biofeedback, chelation therapy, chiropractic services and electrical stimulation are addressed under separate Aetna policies. Many other interventions are listed as experimental, investigational or unproven, including intravenous micronutrient therapy (Myers' Cocktail), Gua Sha, colon hydrotherapy and the Patricia Kane protocol, and standard benefit plans exclude nutritional supplements and medical marijuana.
Aetna · Identified Aug 15, 2026Medium impact
Chronic Pain Rehabilitation Programs (CPB 0237, reviewed 2026-04-23)
Aetna's Clinical Policy Bulletin 0237 sets medical necessity criteria for chronic pain rehabilitation programs. Outpatient programs are medically necessary when the member has had chronic pain for more than 3 months, has documented failure or inadequate response to standard single-modality treatment, has persistent limitations in daily or social or vocational functioning, and has a physician referral and a pre-program psychological and behavioral health evaluation. Inpatient programs for up to 21 days require refractory pain plus two or more listed intractable pain criteria, and several conditions, including prior failure of an adequate multidisciplinary program, aggressive or violent behavior, and imminent suicidal tendencies, are considered not medically necessary.
Aetna · Identified Aug 14, 2026Medium impact
Drug Testing in Pain Management and Substance Use Disorder Treatment (CPB 0965, reviewed 2026-03-03)
Aetna's clinical policy bulletin on drug testing in pain management and substance use disorder treatment states that presumptive urine drug testing is medically necessary for persons starting treatment in a pain management or substance use disorder program, for persons on chronic opioid therapy who are being monitored for chronic pain, and for suspected overdose, among other listed indications. Definitive testing is medically necessary only when a listed condition applies, such as an inconclusive or inconsistent presumptive result or a disputed presumptive result, while standing orders, broad panels, same-day testing of the same drug from two specimen types, and testing ordered by third parties are considered not medically necessary. The policy was last reviewed 09/01/2026 and its next review date is 10/08/2026.
Aetna · Identified Aug 14, 2026Medium impact
Pulsed Electromagnetic Stimulation (CPB 0175, reviewed 2026-06-23)
High frequency pulsed electromagnetic stimulation, also called therapeutic magnetic resonance, is considered experimental, investigational or unproven for all indications listed, including acute post-operative pain and edema, bone consolidation, cancer, chronic low back pain, osteoarthritis, osteoporosis, Parkinson's disease, soft tissue injuries, tendinopathy and wounds. Transcutaneous low frequency pulsed electromagnetic stimulation is considered experimental, investigational or unproven for chronic pain including low back pain, fibromyalgia, hand tremors in Parkinson's disease, osteoarthritis, multiple sclerosis spasticity, neuropathic pain and wounds. CPT 0766T and 0767T, and HCPCS E0761, G0295 and G0329, are listed as not covered for the indications in the policy, and intermittent pulsed electromagnetic stimulation for fracture healing is addressed in CPB 0343 Bone Growth Stimulators.
Aetna · Identified Aug 13, 2026Medium impact
Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-06-03)
Aetna considers TENS medically necessary durable medical equipment as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic intractable pain not adequately responsive to other methods such as physical therapy and pharmacotherapy. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when the member meets all listed criteria, including a successful percutaneous stimulation trial that resulted in at least a 50% reduction in pain for a minimum of 3 days. TENS for chronic low back pain, PENS for opioid withdrawal, and many other electrical stimulation devices and indications are considered experimental, investigational, or unproven.
Independence Blue Cross · Effective Dec 29, 2025Low impact
05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
Independence Blue Cross reissued medical policy 05.00.74l on 10/28/2026 with no substantive changes to TENS device coverage criteria. The policy clarifies medically necessary criteria for chronic pain (other than lower back pain) and experimental/investigational criteria. A prior change effective 12/29/2025 removed a specific pain reduction threshold requirement (50% reduction) from continued coverage criteria. This is a reissue communicating the company's continuing position; verify current applicability for your practice's active plans.
Independence Blue Cross · Effective Oct 1, 2025Low impact
05.00.74k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
Independence Blue Cross updated TENS policy 05.00.74k to 05.00.74l, replacing the single ICD-10 code R10.2 (Pelvic and perineal pain) with four more specific codes (R10.21, R10.22, R10.23, R10.24) effective 10/01/2025. This is a routine ICD-10 CM coding update to align with current coding specificity requirements; coverage criteria and billing codes remain unchanged.

Watch G89.4

Get one email when a payer policy names G89.4, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code G89.4?

There are 22 tracked policy changes affecting code G89.4, including updates from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G89.4?

Payers that have issued tracked updates for code G89.4 include: Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Independence Blue Cross, Aetna.

How do I get notified when code G89.4 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G89.4. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G89.4?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Urine Drug Testing 2.02.50

Urine Drug Testing

MA05.006l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies

05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies

MA05.006k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies

Motor Cortex Stimulation (CPB 0755, reviewed 2026-10-21)

Ziconotide (Prialt) (CPB 0712, reviewed 2026-10-14)

Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-10-14)

Drug Testing in Pain Management and Substance Use Disorder Treatment (CPB 0965, reviewed 2026-09-01)

Thalamotomy (CPB 0153, reviewed 2026-03-30)

Nerve Blocks (CPB 0863, reviewed 2026-07-23)

Motor Cortex Stimulation (CPB 0755, reviewed 2026-02-24)

Seat Lifts and Patient Lifts (CPB 0459, reviewed 2026-07-16)

Laboratory Tests for Depression and Other Psychiatric Disorders (CPB 0306, reviewed 2026-06-08)

Fecal Bacteriotherapy (CPB 0844, reviewed 2026-03-25)

Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)

Chronic Pain Rehabilitation Programs (CPB 0237, reviewed 2026-04-23)

Drug Testing in Pain Management and Substance Use Disorder Treatment (CPB 0965, reviewed 2026-03-03)

Pulsed Electromagnetic Stimulation (CPB 0175, reviewed 2026-06-23)

Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-06-03)

05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies

05.00.74k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies

What insurance policy changes affect code G89.4?

Which payers have updated policy for code G89.4?

How do I get notified when code G89.4 policy changes?

Why do payers change policies for code G89.4?